Please assess the completion status of the following clinical trial:

Trial Title: CONCERTA Lab School Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ADHD diagnosis of all subtypes (except Not Otherwise Specified)~* Patients with total or subscale Attention Deficit Hyperactivity Disorder Rating Scale (ADHD RS-IV) scores \> =90th percentile relative to the general population of children by age and gender~* Patients currently receiving ADHD medication must be inadequately managed on their current stimulant dose and meet this criteria at the screening visit~* Ability to read and understand English~* Ability to attend school regularly~Exclusion Criteria:~* Estimated Full Scale IQ score of 80 or below, Severe Learning Disability~* History of or current, primary diagnosis of: severe anxiety disorder, conduct disorder, psychotic disorders, Pervasive Developmental Disorder, Eating Disorder, Obsessive-Compulsive Disorder, Sleep Disorder, Major Depressive Disorder, Bipolar Disorder, Substance Use Disorder, Chronic Tic Disorder, personal or family history of Tourette's Syndrome~* Weight \< 3rd percentile for age~* History of hospitalization for treatment of a mood, anxiety, or psychotic disorder~* History of failed response to methylphenidate

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
- 2 (Type: EXPERIMENTAL): CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1

Based on this trial design, predict the completion outcome and termination type (if applicable).